Optimize Regeneration Using
the Purest and Most Potent
Tissue Allograft
For homologous use only.
Introducing
GO FAR BEYOND SINGLE MATERIAL ALLOGRAFT
TO FOUR MATERIALS:
“Single birth” donor derived placenta, amnion membrane, Wharton’s jelly, and amniotic fluid meet regulations as are not combined multiple donor material.
GO FAR BEYOND OUTDATED INVASIVE ADIPOSE AND BONE MARROW ASPIRATE TO OFF THE SHELF INJECTABLES
The Facts About Bone Marrow Aspirate
RICHGEN Comparison Chart
Available in 0.5 ml, 1 ml, and 2 ml vials
- • Single donor FOUR materials
- • Full flexible signaling messaging
- • All 1,500 growth factor proteins
- • CD73, CD90, CD105, CD106, Stro-1
- • Exosomes, cytokines, secretomes, miRNA
- • Reduce time, eliminating surgery
- • Cells are never centrifuged
- • New manufacturer is an independent FDA certified
processing lab that is also AATB certified.
Manufactured per 21 CFR 1271.10(a), PHS 361 and
per AATB, GMP, cGMP, and cGTP guidelines.
- • Collagen substrates II, IV, V and VII
- • Undifferentiated pluripotent and multipotent
- • Fibroblasts, Keratinocytes
- • Epithelial & Endothelial cells
- • Reduce liability, eliminating surgery
- • Provide patients non-invasive choice
- • Only freeze outer membrane of cells
- • For homologous use only
- • Does not contain umbilical cord blood
- • FDA Exemption 1271.3 (2) (bb)
Additional RICHGEN Products:
THERAPY
LASER THERAPY
Physicians
RICHGEN unparalleled products are
undifferentiated pluripotent cellular
components with all supporting growth
factors, bioactive cytokines and other
enhancing components.
The RICHGEN flowable allograft injectables are immunomodulating and they have the ability to secrete via exosomes and vesicles the appropriate combination of growth factors and miRNA to influence the surrounding tissue to regenerate.
The extracellular and intracellular messaging from the RICHGEN growth factors BMP 4, 5 and 7 enhance bone growth, the alpha2 macroglobulin enhances anti-inflammatory activity in the joints, the collagen substrates I, III, IV, V and VI, fibronectin and laminin enhance wound healing. The allograft has an immuno-modulating effect on the macrophages and CD45 expresses T cell activation. The placental allograft components drive the development of fully functional cellular repair and regeneration. Bone marrow development,the cells tend to lend themselves to marginally functional cellular development and the cells express inflexible signaling instructions. The RICHGEN cellular components have an immuno-modulatory effect and a trophic effect. In addition, RICHGEN products are never centrifuged and not combined with millions of lecithin that can artificially increase cell counts. RICHGEN is a pure product carefully prepared for maximum effect and safety.
Umbilical cord blood cells are multi-potent, do not differentiate and are made with multiple donor blood often leaving RBCs in the product and have caused host adverse reactions and infections. To create optimization inject using RICHGEN, single donor material flowable allograft. What's more, RICHGEN's important proprietary processing does not crystallize the inner cells in the freezing process, just the outer membrane. The result is our thawed product is the most leading edge today. Doctors have ease of use and time savings. Please visit the Physician Portal.
Welcome to RichSource
RICHGEN Tissue Allograft
The most bioactive human tissue allograft regenerative combination products on the market - are here.
Yes, after years of research and development all four materials are carefully prepared by our new manufacturer in an independent FDA certified and registered tissue processing lab in Florida, USA. The lab is also AATB certified. The biologics are regulated as human cellular or tissue-based product (HCT/P) under 21 CFR Part 1271.10 and Section 361 of the Public Health Service Act, FDA and ISO 13485 guidelines. FDA, AATB, cGMP and cGTP compliant. Years of research and testing of single donor placenta, Wharton’s jelly, amniotic fluid, and amnion membrane enrich and make RICHGEN products the superior choice. See FDA Publication of 21 CFR 1271 legal interpretation of PHSA section 351 v 361 that 361 manufacturing is allowed.
The RICHGEN flowable allografts’ bioactive proteins, combined with the presence of the extracellular matrix, laminin, and fibronectin, present a functional allograft that is effective in a wide array of applications. The applications range from topical wound healing to rapid response for use in orthopedic pathologies, organ system pathologies, pain / anti-inflammatory control, scar management by following the inflammatory chemotactic pathways and providing components, immunomodulation, and scaffolding for healthy tissue generation and repair of injured tissue. For homologous use only.
RICHGEN Injectables
Physicians nationwide have advanced
their practices with RICHGEN off the shelf injectables.
Using RICHGEN products provide your patients with non-invasive, non-surgical options. Even better, they will save you time, reduce your liability and bring in a new revenue stream. Additionally, Login and see our 100% guaranteed payment plan for patient treatments using RichSource distributed RICHGEN products.
Caution: Click here for information regarding use of inferior brands
or procedures in violation of FDA and PHSA.
Aestheticians
We invite you to look into our new RICHGEN products to use post-micro-needling collagen induction replacing PRP, post-CO2 lasering, during cool sculpting, post-lipoaspiration or for wellness. RICHGEN is now replacing PRP and PRFP. The RICHGEN Matrix new facial serum is recommended to use post-treatment for 60 days in the morning after and evenings twice a day onward, to further enhance skin regeneration.
See why.
RICHGEN Facial Serum Info Card
NEW RICHGEN MATRIX Regenerative Skin Care Line November 2019. New science and natural ingredients for next generation hydration, nourishment and rejuvenation.
AESTHETICIANS PORTAL
